This video is featured in the 2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Nal-IRI/LV5-FU vs. Paclitaxel as 2L Therapy in Metastatic Esophageal SCC - OESIRI-PRODIGE 62 Study

61 views
September 27, 2024
0 Comments
Login to view comments. Click here to Login